ClinicalTrials.Veeva

Menu

Comparison of the Effects of Neostigmine With Sugammadex on Postoperative Nausea and Vomiting.

T

T.C. ORDU ÜNİVERSİTESİ

Status and phase

Completed
Phase 4

Conditions

Incidence of Postoperative Nausea and Vomiting

Treatments

Drug: sugammadex
Drug: Neostigmine

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Postoperative nausea and vomiting is one of most common complications after general anesthesia. Female sex, history of postoperative nausea and vomiting, motion sickness, non smoker status, opioid administration are known as risk factors for developing postoperative nausea and vomiting.

It has been suggest that antagonism of residual neuromuscular block with a mixture of neostigmine and atropine at the end of the surgery increases the risk of postoperative nausea and vomiting.

Sugammadex is a very safe drug with almost no serious adverse effects. The known adverse effects include slight coughing, movement, an altered taste sensation in the mouth, transient prolongation of the QT interval, hypersensitivity, and a short term prolongation of the activated partial thromboplastin time.

The aim of this study was to compare the sugammadex versus neostigmine plus atropine for reversal of rocuronium induced neuromuscular blockade in terms of incidence of postoperative nausea and vomiting.

Enrollment

98 patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • American Society of Anesthesiologists (ASA) physical status 1 and 2
  • endotracheal intubation and general anesthesia scheduled for elective surgery

Exclusion criteria

  • age < 18 years, > 65 years
  • pregnancy
  • refusal to participate and patients already participating in another study
  • allergy to study drugs
  • communication difficulty
  • psychiatric and neurological disorders
  • use of analgesics or sedative or antiemetic drugs within 24 hours before surgery.
  • emergency surgery
  • history of drug or alcohol abuse
  • ASA 3 and above
  • patients with vertigo
  • Laparoscopic surgery, oncologic surgery, strabismus and mid ear surgery neurosurgery, gynecologic surgery, breast surgery

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Single Blind

98 participants in 2 patient groups

neostigmine
Active Comparator group
Treatment:
Drug: Neostigmine
sugammadex
Active Comparator group
Treatment:
Drug: sugammadex

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems